Obsidian Therapeutics (NASDAQ:OBX) Stock Moved Up to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Obsidian Therapeutics (NASDAQ:OBX) from a sell rating to a hold rating in a report published on Sunday morning,Wall Street Zen reports.

Several other research firms have also recently issued reports on OBX. William Blair upgraded shares of Obsidian Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Lifesci Capital assumed coverage on shares of Obsidian Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price target for the company. TD Cowen began coverage on shares of Obsidian Therapeutics in a report on Thursday, August 6th. They issued a “buy” rating on the stock. Leerink Partners began coverage on shares of Obsidian Therapeutics in a report on Tuesday, September 22nd. They issued an “outperform” rating and a $32.00 price target on the stock. Finally, Piper Sandler assumed coverage on Obsidian Therapeutics in a research report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $39.00.

Obsidian Therapeutics Price Performance

OBX stock opened at $13.98 on Friday. The company has a 50 day moving average price of $15.74. Obsidian Therapeutics has a 12 month low of $11.52 and a 12 month high of $49.97.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.